0001703057-23-000024.txt : 20230809 0001703057-23-000024.hdr.sgml : 20230809 20230809122200 ACCESSION NUMBER: 0001703057-23-000024 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hayden Michael R CENTRAL INDEX KEY: 0001352908 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39781 FILM NUMBER: 231154231 MAIL ADDRESS: STREET 1: C/O ASPREVA PHARMACEUTICALS CORPORATION STREET 2: 1203-4464 MARKHAM STREET CITY: VICTORIA STATE: A1 ZIP: V8Z 7X8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbCellera Biologics Inc. CENTRAL INDEX KEY: 0001703057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 BUSINESS PHONE: (604) 559-9005 MAIL ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 4 1 wk-form4_1691598110.xml FORM 4 X0508 4 2023-08-08 0 0001703057 AbCellera Biologics Inc. ABCL 0001352908 Hayden Michael R C/O ABCELLERA BIOLOGICS INC 2215 YUKON STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA 1 0 0 0 0 Common Shares 2023-08-08 5 P 0 E 30000 5.90 A 1303397 I See footnote Common Shares 118245 I By spouse The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $5.89 to $5.91. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. Tryn Stimart, attorney-in-fact 2023-08-09